August 17, 2021 (Newswire.com) –
Woodward Pharma Providers LLC (“Woodward”), a Michigan-based specialty pharmaceutical firm targeted on buying, licensing and commercializing branded and generic merchandise for the U.S. market, declares the acquisition of LOVAZA® (LO-VEY-ZA) smooth gelatin capsules.
LOVAZA® (omega-3-acid ethyl esters) capsules are indicated as an adjunct to weight-reduction plan to cut back triglyceride ranges in grownup sufferers with extreme (larger than or equal to 500 mg/dL) hypertriglyceridemia. LOVAZA® was the primary prescription omega-3 product accepted by the FDA as a protected, pure and efficient medical-grade complement for managing excessive triglycerides.
“Your complete Woodward workforce is past excited to amass this iconic pharmaceutical model,” mentioned Nirav Patel, President of Woodward. “LOVAZA® has a deep and wealthy heritage within the cardiovascular neighborhood and has served thousands and thousands of sufferers because it was first accepted in 2004. We sit up for persevering with to coach suppliers and customers alike of the advantages of LOVAZA®. We may also put money into affected person help applications, a refreshed web site and life cycle administration methods over the approaching months.” Extra information could be discovered at www.lovaza.com.
Woodward acquired LOVAZA® from GlaxoSmithKline LLC (“GSK”).
About Woodward Pharma Providers LLC
Woodward Pharma Providers LLC is a specialty pharmaceutical firm targeted on buying, licensing, and commercializing branded and generic pharmaceuticals for the U.S. market. The Firm has a various portfolio of merchandise distributed throughout a number of channels.
Contact – Nirav Patel, President – email@example.com
Supply: Woodward Pharma Providers LLC